Wanjia Group Holdings Limited (HKG:0401)
Hong Kong · Delayed Price · Currency is HKD 0.0630
-0.0050 (-7.35%)
Jul 17, 2025, 4:08 PM HKT
Wanjia Group Holdings Revenue
In the fiscal year ending March 31, 2025, Wanjia Group Holdings had annual revenue of 161.69M HKD, down -10.71%. Wanjia Group Holdings had revenue of 78.00M in the half year ending March 31, 2025, a decrease of -6.65%.
Revenue
161.69M
Revenue Growth
-10.71%
P/S Ratio
0.22
Revenue / Employee
893.33K
Employees
181
Market Cap
35.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 161.69M | -19.40M | -10.71% |
| Mar 31, 2024 | 181.09M | 7.39M | 4.25% |
| Mar 31, 2023 | 173.70M | 18.88M | 12.19% |
| Mar 31, 2022 | 154.82M | 40.74M | 35.71% |
| Mar 31, 2021 | 114.09M | 17.11M | 17.64% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |